CAMZYOS (mavacamten) – Hypertrophic cardiomyopathy (HCM) therapy in India
Camzyos is used to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (obstructive HCM). Hypertrophic cardiomyopathy (HCM) is a condition where the walls of the heart chamber (left ventricle) contract harder and become thicker than normal.
| Brand Name: | CAMZYOS |
| Generic Name: | mavacamten |
| Strength: | Capsules: 2.5 mg, 5 mg, 10 mg, and 15 mg |
| Manufacturer: | Bristol-Myers Squibb |
| Approved By: | EMA, USFDA |
Source Details: Patient Information
CAMZYOS must always be used under the supervision of a Registered Medical Practitioner (RMP).
Access CAMZYOS for Hypertrophic cardiomyopathy (HCM) treatment on a Named Patient Import Basis
IPN, New Delhi serves as a facilitator for the procurement of specialized drugs on behalf of patients or treating doctors, enabling access to CAMZYOS (mavacamten) for personal use. To proceed, the applicant must submit an application in Form 12A along with a valid prescription issued by a Registered Medical Practitioner (RMP).
For any queries, including information regarding the cost of the pharmaceutical product in India, please contact the IPN Healthcare Support Team via email or at the following numbers: Mobile/WhatsApp: Mr. Tarun: +91 9891 296 838 | Mr. Neeraj: +91 9811 747 774.
Note: All access is provided strictly on a Named Patient Import Basis and for personal use only, in accordance with Indian regulatory guidelines.
